GlassScriptPhysician profile
Charlotte L Perry
NPI 1184911893
$1,179.29
in general payments reported to CMS, 2019-2025
19 companies · $87.50 in 2025
The $87.50 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $312 · 2023: $287 · 2024: $235 · 2025: $87.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $190.56 | 2021-2023 | |
| Amgen INC. | $172.27 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $156.49 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $150.15 | 2021-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.30 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $48.21 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dynavax Technologies Corporation | $45.40 | 2022-2024 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $40.80 | 2022 | |
| Dexcom, INC. | $34.96 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Glaxosmithkline, LLC. | $34.09 | 2021-2025 | Shingrix, Penmenvy, Bexsero |
| Idorsia Pharmaceuticals US INC | $32.49 | 2023-2024 | Quviviq |
| Myriad Genetic Laboratories, INC. | $32.12 | 2024 | Myrisk |
| Corium, LLC | $29.33 | 2023 | Adlarity |
| Astrazeneca Pharmaceuticals LP | $26.82 | 2021-2023 | Breztri |
| Ardelyx, INC. | $19.38 | 2024 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.80 | 2022 | |
| Neurelis, INC. | $14.75 | 2023 | Valtoco |
| Phathom Pharmaceuticals, INC. | $14.68 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.